Tauriga Sciences Inc. CBD (Cannabidiol) Infused TopiCanna Products Have Been Officially Launched
Los Angeles, CA / ACCESSWIRE / December 16, 2014 / Tauriga Sciences, Inc. (TAUG) (“Tauriga” or the “Company”), a diversified life sciences company with interests in the natural wellness sector and in developing a proprietary synthetic biology platform technology, today launched its first proprietary topical medicinal cannabis cream branded as TopiCanna. TopiCanna contains cannabidiol (CBD) oil from non-GMO industrial hemp that is grown without pesticides, herbicides, or chemical fertilizers. The oil has been lab tested for quality and is natural, safe and legal in the United States and in Japan, where Tauriga has a recently announced MOU with Tokyo-based iFLOW Ltd. There are no psychoactive effects associated with the CBD oil. Tauriga previously announced on November 25, 2014 that the Company planned to launch its TopiCanna product line within the next 60 days. TopiCanna’s launch occurred well within the projected timeline. Initially the TopiCanna Products be sold directly by Tauriga Sciences, Inc. (interested parties may email inquiries to email@example.com). The Company plans to expand TopiCanna’s sales and marketing efforts to include online sales and distribution agreements, both domestically and internationally.
Many people who have used topical cannabis creams have reported decreased musculoskeletal pain. As such, the Company’s first TopiCanna product is designed to provide potential wellness and healing properties without narcotic effects. In addition to the CBD oil from non-GMO industrial hemp, the lotion contains ingredients for soothing dry skin.
Tauriga is also currently producing its first run of CannaCaviar soft gels using high-CBD, low-THC oil that has been extracted from the stalk of the cannabis plant. CannaCaviar is included in the recently announced MOU with iFLOW Ltd. The Company anticipates launching CannaCaviar before the end of the calendar year.
In addition to the progress on Tauriga’s CBD-containing products for the US and Japan, the Company would like to provide an update on other efforts. Tauriga is pleased to announce that the Company launched its new corporate website (www.tauriga.com) last week. The new site has provides more extensive content and has links to the company’s Facebook and Twitter pages for information that does not rise to the level of a press release. Tauriga is also on target for launching its e-commerce website e-commerce website (www.taurigastore.com) later this month to sell its non-cannabis containing line of natural wellness dietary supplements. These natural supplements include IndiCalm, natural calming formula without inducing cognitive impairment; ClearNaze, a natural decongestant without stimulant or drowsiness effects; Satietiva, an amino acid-based appetite suppressant; and EndoCannabinoid Omega-3 Support (or MendOCan), a highly pure, potent and palatable Omega 3 supplement. Interested customers will be able to purchase these cannabis-free products online when the site is launched before the end of the year.
Tauriga’s Chairman & CEO Dr. Stella Sung commented, “We are proud of our efforts in building a revenue-generating company in natural wellness and cleantech, and we appreciate our shareholders for sharing our vision and our commitment.”
About Tauriga Sciences, Inc.
Tauriga Sciences, Inc. (TAUG) is a diversified life sciences company focused on generating profitable revenues in the natural wellness sector and in developing a proprietary synthetic biology platform technology. The mission of the Company is to acquire and build a balanced portfolio of cutting edge technology assets that is capital efficient and of significant value to the shareholders. The Company’s business model includes the acquisition of licenses, equity stakes, rights on both an exclusive and non-exclusive basis, and entire businesses. Management is firmly committed to building lasting shareholder value in the short, intermediate, and long terms. Please visit the Company’s corporate website at www.tauriga.com.
Forward-Looking Statements: Except for statements of historical fact, this news release contains certain “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995, including, without limitation expectations, beliefs, plans and objectives regarding the development, use and marketability of products. Such forward-looking statements are based on present circumstances and on the Company’s predictions with respect to events that have not occurred, that may not occur, or that may occur with different consequences and timing than those now assumed or anticipated. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, and are not guarantees of future performance or results and involve risks and uncertainties that could cause actual events or results to differ materially from the events or results expressed or implied by such forward-looking statements. Such factors include general economic and business conditions, the ability to successfully develop and market products, consumer and business consumption habits, the ability to fund operations and other factors over which the Company has little or no control. Such forward-looking statements are made only as of the date of this release, and the Company assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances. Readers should not place undue reliance on these forward-looking statements. Risks, uncertainties and other factors are discussed in documents filed from time to time by the Company with the Securities and Exchange Commission. This press release does not and shall not constitute an offer to sell or the solicitation of any offer to buy any of the securities, nor shall there be any sale of the securities, in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state. The securities have not been registered under the Securities Act of 1933, as amended (the “Securities Act”) or any state securities laws, and may not be offered or sold in the United States absent registration, or an applicable exemption from registration, under the Securities Act and applicable state securities laws.
Food and Drug Administration Disclaimer: None of the statements contained in this press release regarding any of the products either offered or to be offered in the future by the Company have been evaluated by the Food and Drug Administration. Additionally, none of the products is intended to diagnose, treat, cure, or prevent any disease.
Tauriga Sciences, Inc.:
Dr. Stella M. Sung,
Chairman and Chief Executive Officer
Tauriga Sciences, Inc.
San Diego: + 1-858-353-5749
Montreal: + 1-514-840-3697
SOURCE: Tauriga Sciences, Inc.
MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | firstname.lastname@example.org